Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2010

Open Access 01-12-2010 | Review

Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment

Authors: Giuseppe Castello, Susan Costantini, Stefania Scala

Published in: Journal of Translational Medicine | Issue 1/2010

Login to get access

Abstract

Epidemiological, preclinical and clinical studies demonstrated that chronic inflammation induced by hepatitis C virus (HCV) is crucial in hepatocellular carcinogenesis. The interaction between hepatocytes and microenvironment regards virus, inflammatory and immunocompetent cells, chemo- and cyto-kines, reactive oxygen species (ROS) and nitric oxide (NO), generating cell transformation. We suggest hepatocarcinoma (HCC) as a model in which the targeting of microenvironment determine neoplastic transformation. The present review focuses on: the role of inflammation in carcinogenesis, the clinical impact of HCC and the inadequacy of the actual therapy, the chemoprevention targeting the microenvironment.
Appendix
Available only for authorised users
Literature
1.
Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005. J Clin Oncol. 2009, 27 (9): 1485-91. 10.1200/JCO.2008.20.7753.PubMedPubMedCentral
2.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer Statistics 2007. CA Cancer J Clin. 2007, 57 (1): 43-66. 10.3322/canjclin.57.1.43.PubMed
3.
El-Serag HB, Rudolph KL: Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology. 2007, 132 (7): 2557-76. 10.1053/j.gastro.2007.04.061.PubMed
4.
Castello G, Scala S, Palmieri G, Curley SA, Izzo F: HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol. 2010, 134 (3): 237-50. 10.1016/j.clim.2009.10.007.PubMed
5.
Fassio E: Hepatitis C and hepatocellular carcinoma. Ann Hepatol. 2010, 9: 119-22.PubMed
6.
Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C: Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology. 2008, 48 (1): 137-45. 10.1002/hep.22312.PubMed
7.
Fusco M, Girardi E, Piselli P, Palombino R, Polesel J, Maione C, Scognamiglio P, Pisanti FA, Solmone M, Di Cicco P, Ippolito G, Franceschi S, Serraino D: Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer. 2008, 44 (6): 847-53. 10.1016/j.ejca.2008.01.025.PubMed
8.
Ryder SD: British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003, 52: 1-8. 10.1136/gut.52.suppl_3.iii1.
9.
Nash KL, Woodall T, Brown AS, Davies SE, Alexander GJ: Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis. World J Gastroenterol. 2010, 16 (32): 4061-5. 10.3748/wjg.v16.i32.4061.PubMedPubMedCentral
10.
Chiesa R, Donato F, Tagger A, Favret M, Ribero ML, Nardi G, Gelatti U, Bucella E, Tomasi E, Portolani N, Bonetti M, Bettini L, Pelizzari G, Salmi A, Savio A, Garatti M, Callea F: Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiology, Biomarkers & Prevention. 2000, 9: 213-6.
11.
Anzola M: Hepatocellular Carcinoma: Role of Hepatitis B and Hepatitis C Viruses Proteins in Hepatocarcinogenesis. J Viral Hepat. 2004, 11 (5): 383-93. 10.1111/j.1365-2893.2004.00521.x.PubMed
12.
Paterlini-Bréchot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, Lagorce D, Bréchot C: Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene. 2003, 22: 3911-3916. 10.1038/sj.onc.1206492.PubMed
13.
Cougot D, Neuveut C, Buendia MA: HBV induced carcinogenesis. J Clinical Virology. 2005, 34: S75-S78. 10.1016/S1386-6532(05)80014-9.
14.
Bowen DG, Walker CM: Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005, 436 (7053): 946-52. 10.1038/nature04079.PubMed
15.
Ueno Y, Sollano JD, Farrell GC: Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol. 2009, 24 (4): 531-6. 10.1111/j.1440-1746.2009.05814.x.PubMed
16.
Tosi MF: Innate immune responses to infection. J Allergy Clin Immunol. 2005, 116 (2): 241-9. 10.1016/j.jaci.2005.05.036.PubMed
17.
Li Z, Diehl AM: Innate immunity in the liver. Curr Opin Gastroenterol. 2003, 19 (6): 565-71. 10.1097/00001574-200311000-00009.PubMed
18.
Norris S, Collins C, Doherty DG, Smith F, McEntee G, Traynor O, Nolan N, Hegarty J, O'Farrelly C: Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol. 1998, 28 (1): 84-90. 10.1016/S0168-8278(98)80206-7.PubMed
19.
Mehal WZ, Azzaroli F, Crispe IN: Immunology of the healthy liver: old questions and new insights. Gastroenterology. 2001, 120 (1): 250-60. 10.1053/gast.2001.20947.PubMed
20.
Rehermann B: Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009, 119 (7): 1745-54. 10.1172/JCI39133.PubMedPubMedCentral
21.
Thompson JM, Iwasaki A: Toll-like receptors regulation of viral infection and disease. Adv Drug Deliv Rev. 2008, 60 (7): 786-94. 10.1016/j.addr.2007.11.003.PubMedPubMedCentral
22.
Gale M, Foy EM: Evasion of intracellular host defence by hepatitis C virus. Nature. 2005, 436 (7053): 939-45. 10.1038/nature04078.PubMed
23.
Zhang X, Dou J, Germann MW: Characterization of the cellular immune response in hepatitis C virus infection. Med Res Rev. 2009, 29 (6): 843-66. 10.1002/med.20157.PubMed
24.
Sklan EH, Charuworn P, Pang PS, Glenn JS: Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol. 2009, 6 (4): 217-27. 10.1038/nrgastro.2009.32.PubMed
25.
Kanto T, Hayashi N: Innate immunity in hepatitis C virus infection: Interplay among dendritic cells, natural killer cells and natural killer T cells. Hepatol Res. 2007, 3: S319-26. 10.1111/j.1872-034X.2007.00236.x.
26.
Takahashi K, Asabe S, Wieland S, Garaigorta U, Gastaminza P, Isogawa M, Chisari FV: From the Cover: Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. PNAS. 2010, 107 (16): 7431-7436. 10.1073/pnas.1002301107.PubMedPubMedCentral
27.
Ahlenstiel G, Booth DR, George J: IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol. 2010
28.
Canning C, O'Brien M, Hegarty J, O'Farrelly C: Liver immunity and tumour surveillance. Immunol Lett. 2006, 107 (2): 83-8. 10.1016/j.imlet.2006.07.002.PubMed
29.
Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001, 194 (10): 1395-406. 10.1084/jem.194.10.1395.PubMedPubMedCentral
30.
Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH, Chisari FV: Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA. 2002, 99 (24): 15661-8. 10.1073/pnas.202608299.PubMedPubMedCentral
31.
Jinushi M, Takehara T, Kanto T, Tatsumi T, Groh V, Spies T, Miyagi T, Suzuki T, Sasaki Y, Hayashi N: Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol. 2003, 170 (3): 1249-56.PubMed
32.
Auffermann-Gretzinger S, Keeffe EB, Levy S: Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood. 2001, 97 (10): 3171-6. 10.1182/blood.V97.10.3171.PubMed
33.
Dolganiuc A, Kodys K, Kopasz A, Marshall C, Do T, Romics L, Mandrekar P, Zapp M, Szabo G: Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol. 2003, 170 (11): 5615-24.PubMed
34.
Masuzaki R, Yoshida H, Omata M: Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Oncology. 2010, 78: 17-23. 10.1159/000315225.PubMed
35.
Guidotti LG, Chisari FV: Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001, 19: 65-91. 10.1146/annurev.immunol.19.1.65.PubMed
36.
Frese M, Schwärzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, Bartenschlager R: Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology. 2002, 35 (3): 694-703. 10.1053/jhep.2002.31770.PubMed
37.
Durante-Mangoni E, Wang R, Shaulov A, He Q, Nasser I, Afdhal N, Koziel MJ, Exley MA: Hepatic CD1 d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol. 2004, 173 (3): 2159-66.PubMed
38.
Wiltrout RH: Regulation and antimetastatic functions of liver associated natural killer cells. Immunol Rev. 2000, 174: 63-76. 10.1034/j.1600-0528.2002.00014h.x.PubMed
39.
De Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A, Nuti S, Colombo M, Callea F, Porcelli SA, Panina-Bordignon P, Abrignani S, Casorati G, Dellabona P: Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol. 2004, 173 (2): 1417-25.PubMed
40.
Grüner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, Hoffmann R, Zachoval R, Santantonio T, Cucchiarini M, Cerny A, Pape GR: Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis. 2000, 181 (5): 1528-36. 10.1086/315450.PubMed
41.
Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, Chung RT, Walker BD: Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol. 2002, 76 (24): 12584-95. 10.1128/JVI.76.24.12584-12595.2002.PubMedPubMedCentral
42.
Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B: Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000, 6 (5): 578-82. 10.1038/75063.PubMed
43.
Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD: Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000, 191 (9): 1499-512. 10.1084/jem.191.9.1499.PubMedPubMedCentral
44.
Grasl-Kraupp B, Rossmanith W, Ruttkay-Nedecky B, Müllauer L, Kammerer B, Bursch W, Schulte-Hermann R: Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia. Hepatology. 1998, 28 (3): 717-26. 10.1002/hep.510280318.PubMed
45.
Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM: Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology. 2003, 38 (6): 1437-48.PubMed
46.
Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, Nelson DR: An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology. 2004, 40 (5): 1062-71. 10.1002/hep.20454.PubMed
47.
Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, Blum HE, von Weizsäcker F, Thimme R: T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol. 2005, 79 (12): 7860-7. 10.1128/JVI.79.12.7860-7867.2005.PubMedPubMedCentral
48.
Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005, 65 (6): 2457-64. 10.1158/0008-5472.CAN-04-3232.PubMed
49.
Huang YS, Hwang SJ, Chan CY, Wu JC, Chao Y, Chang FY, Lee SD: Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yi Xue Za Zhi (Taipei). 1999, 62 (6): 327-33.
50.
Budhu A, Wang XW: The role of cytokines in hepatocellular carcinoma. J Leukoc Biol. 2006, 80 (6): 1197-213. 10.1189/jlb.0506297.PubMed
51.
Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, Hayakawa Y, Kinoshita H, Yamakado M, Kato N, Shiina S, Omata M: Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: An analysis based on gender differences. Int J Cancer. 2009, 125 (10): 2264-9. 10.1002/ijc.24720.PubMed
52.
Capone F, Costantini S, Guerriero E, Calemma R, Napolitano M, Scala S, Izzo F, Castello G: Cytokine serum levels in patients with hepatocellular carcinoma. Eur Cytok Net. 2010, 21 (2):
53.
Seitz HK, Stickel F: Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem. 2006, 387 (4): 349-60. 10.1515/BC.2006.047.PubMed
54.
Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C: Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007, 121 (11): 2381-6. 10.1002/ijc.23192.PubMed
55.
Hussain SP, Hofseth LJ, Harris CC: Radical causes of cancer. Nat Rev Cancer. 2003, 3 (4): 276-85. 10.1038/nrc1046.PubMed
56.
57.
Pal S, Polyak SJ, Bano N, Qiu WC, Carithers RL, Shuhart M, Gretch DR, Das A: Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol. 2010, 25 (3): 627-34. 10.1111/j.1440-1746.2009.06128.x.PubMedPubMedCentral
58.
Farinati F, Cardin R, Bortolami M, Burra P, Russo FP, Rugge M, Guido M, Sergio A, Naccarato R: Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. J Viral Hepat. 2007, 14 (12): 821-9.PubMed
59.
Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, Fujii H, Rusyn I: Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol. 2007, 14 (3): 1182-90. 10.1245/s10434-006-9049-1.PubMed
60.
Adelman R, Saul RL, Ames BN: Oxidative damage to DNA: relation to species metabolic rate and life span. Proc Natl Acad Sci USA. 1988, 85 (8): 2706-8. 10.1073/pnas.85.8.2706.PubMedPubMedCentral
61.
Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H: Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol. 2000, 95 (4): 1041-50. 10.1111/j.1572-0241.2000.01979.x.PubMed
62.
Konishi M, Iwasa M, Araki J, Kobayashi Y, Katsuki A, Sumida Y, Nakagawa N, Kojima Y, Watanabe S, Adachi Y, Kaito M: Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol Hepatol. 2006, 21 (12): 1821-5. 10.1111/j.1440-1746.2006.04420.x.PubMed
63.
Mahmood S, Kawanaka M, Kamei A, Izumi A, Nakata K, Niiyama G, Ikeda H, Hanano S, Suehiro M, Togawa K, Yamada G: Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid Redox Signal. 2004, 6 (1): 19-24. 10.1089/152308604771978318.PubMed
64.
Hara Y, Hino K, Okuda M, Furutani T, Hidaka I, Yamaguchi Y, Korenaga M, Li K, Weinman SA, Lemon SM, Okita K: Hepatitis C virus core protein inhibits deoxycholic acidmediated apoptosis despite generating mitochondrial reactive oxygen species. J Gastroenterol. 2006, 41 (3): 257-68. 10.1007/s00535-005-1738-1.PubMed
65.
Seronello S, Sheikh MY, Choi J: Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Radic Biol Med. 2007, 43 (6): 869-82. 10.1016/j.freeradbiomed.2007.05.036.PubMed
66.
Choi SH, Hwang SB: Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein. J Biol Chem. 2006, 281 (11): 7468-78. 10.1074/jbc.M512438200.PubMed
67.
Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, Carithers RL, Larson AM, Yeh MM, Camp DG, Smith RD, Katze MG: Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology. 2007, 46 (3): 649-57. 10.1002/hep.21751.PubMed
68.
Levrero M: Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006, 25 (27): 3834-47. 10.1038/sj.onc.1209562.PubMed
69.
Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH: Use of Yttrium-90 Microspheres in Patients with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis. J Vasc Interv Radiol. 2010, 21 (9): 1377-1384. 10.1016/j.jvir.2010.04.027.PubMedPubMedCentral
70.
Bishayee A, Politis T, Darvesh AS: Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev. 2010, 36 (1): 43-53. 10.1016/j.ctrv.2009.10.002.PubMed
71.
Pirola L, Fröjdö S: Resveratrol: one molecule, many targets. IUBMB Life. 2008, 60 (5): 323-32. 10.1002/iub.47.PubMed
72.
Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL: Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009, 486 (2): 95-102. 10.1016/j.abb.2009.01.018.PubMedPubMedCentral
73.
Hu KQ: Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med. 2002, 139 (4): 234-43. 10.1067/mlc.2002.122281.PubMed
74.
Lim K, Han C, Dai Y, Shen M, Wu T: Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther. 2009, 8 (11): 3046-55. 10.1158/1535-7163.MCT-09-0551.PubMedPubMedCentral
75.
Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H, Moriwaki H: Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett. 2009, 285 (2): 210-7. 10.1016/j.canlet.2009.05.019.PubMed
76.
Tatebe H, Shimizu M, Shirakami Y, Tsurumi H, Moriwaki H: Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res. 2008, 14 (9): 2806-12. 10.1158/1078-0432.CCR-07-4708.PubMed
77.
Pascale RM, Simile MM, De Miglio MR, Nufris A, Daino L, Seddaiu MA, Rao PM, Rajalakshmi S, Sarma DS, Feo F: Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis. 1995, 16 (2): 427-30. 10.1093/carcin/16.2.427.PubMed
78.
Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin JK, Lai GM, Hsieh CY, Cheng AL: Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis. 2000, 21 (2): 331-5. 10.1093/carcin/21.2.331.PubMed
79.
Maruyama S, Nagasue N, Dhar DK, Yamanoi A, El-Assal ON, Satoh K, Okita K: Preventive effect of FK143, a 5alpha-reductase inhibitor, on chemical hepatocarcinogenesis in rats. Clin Cancer Res. 2001, 7 (7): 2096-104.PubMed
80.
Kakizaki S, Takagi H, Fukusato T, Toyoda M, Horiguchi N, Sato K, Takayama H, Nagamine T, Mori M: Effect of alpha-tocopherol on hepatocarcinogenesis in transforming growth factor-alpha (TGF-alpha) transgenic mice treated with diethylnitrosamine. Int J Vitam Nutr Res. 2001, 71 (5): 261-7. 10.1024/0300-9831.71.5.261.PubMed
81.
Basak R, Bhattacharya R, Chatterjee M: 1 alpha,25-Dihydroxyvitamin D(3) inhibits rat liver ultrastructural changes in diethylnitrosamine-initiated and phenobarbital promoted rat hepatocarcinogenesis. J Cell Biochem. 2001, 81 (2): 357-67. 10.1002/1097-4644(20010501)81:2<357::AID-JCB1050>3.0.CO;2-Q.PubMed
82.
Qin G, Ning Y, Lotlikar PD: Chemoprevention of aflatoxin B1-initiated and carbon tetrachloride-promoted hepatocarcinogenesis in the rat by green tea. Nutr Cancer. 2000, 38 (2): 215-22. 10.1207/S15327914NC382_11.PubMed
83.
Singh BN, Singh BR, Sarma BK, Singh HB: Potential chemoprevention of N-nitrosodiethylamine-induced hepatocarcinogenesis by polyphenolics from Acacia nilotica bark. Chem Biol Interact. 2009, 181 (1): 20-8. 10.1016/j.cbi.2009.05.007.PubMed
84.
Boots AW, Haenen GR, Bast A: Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008, 585 (2-3): 325-337. 10.1016/j.ejphar.2008.03.008.PubMed
85.
Matsumoto S, Jin M, Dewa Y, Nishimura J, Moto M, Murata Y, Shibutani M, Mitsumori K: Suppressive effect of Siraitia grosvenorii extract on dicyclanil-promoted hepatocellular proliferative lesions in male mice. J Toxicol Sci. 2009, 34 (1): 109-18. 10.2131/jts.34.109.PubMed
86.
Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP: Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev. 2009, 18 (1): 13-25. 10.1097/CEJ.0b013e3282f0c090.PubMed
87.
Murugan RS, Uchida K, Hara Y, Nagini S: Black tea polyphenols modulate xenobiotic-metabolizing enzymes, oxidative stress and adduct formation in a rat hepatocarcinogenesis model. Free Radic Res. 2008, 42 (10): 873-84. 10.1080/10715760802506331.PubMed
88.
Ho YC, Liu CH, Chen CN, Duan KJ, Lin MT: Inhibitory effects of xanthohumol from hops (Humulus lupulus L.) on human hepatocellular carcinoma cell lines. Phytother Res. 2008, 22 (11): 1465-8. 10.1002/ptr.2481.PubMed
89.
Kuroiwa-Trzmielina J, de Conti A, Scolastici C, Pereira D, Horst MA, Purgatto E, Ong TP, Moreno FS: Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug. Int J Cancer. 2009, 124 (11): 2520-7. 10.1002/ijc.24212.PubMed
90.
Jagan S, Ramakrishnan G, Anandakumar P, Kamaraj S, Devaki T: Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat hepatocellular carcinoma. Mol Cell Biochem. 2008, 319 (1-2): 51-9. 10.1007/s11010-008-9876-4.PubMed
91.
Glauert HP, Calfee-Mason K, Stemm DN, Tharappel JC, Spear BT: Dietary antioxidants in the prevention of hepatocarcinogenesis: A review. Mol Nutr Food Res. 2010, 54 (7): 875-96. 10.1002/mnfr.200900482.PubMed
92.
Reeves PG, Nielsen FH, Fahey GC: AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A diet. J Nutr. 1993, 123: 1939-1951.PubMed
93.
Bjorkhem-Bergman L, Torndal UB, Eken S, Nystrom C, Capitanio A, Larsen EH, Björnstedt M, Eriksson LC: Selenium prevents tumor development in a rat model for chemical carcinogenesis. Carcinogenesis. 2005, 26: 125-131. 10.1093/carcin/bgh290.PubMed
94.
Borbath I, Leclercq IA, Sempoux C, Abarca-Quinones J, Desaeger C, Horsmans Y: Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chem Biol Interact. 2010, 183 (1): 238-48. 10.1016/j.cbi.2009.10.011.PubMed
95.
Craxì A, Cammà C: Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons. Dig Liver Dis. 2010, 42: S287-92. 10.1016/S1590-8658(10)60518-X.PubMed
96.
Romeo R, Pol S, Berthelot P, Brechot C: Eradication of Hepatitis C Virus RNA after Alpha-Interferon Therapy. Annals of Internal Medicine. 1994, 121: 276-277.PubMed
97.
Miyake Y, Takaki A, Iwasaki Y, Yamamoto K: Meta-analysis: Interferon-alpha Prevents the Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. J Viral Hepat. 2010, 17 (4): 287-292. 10.1111/j.1365-2893.2009.01181.x.PubMed
98.
Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL, HALT-C Trial Investigators: Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008, 359 (23): 2429-41. 10.1056/NEJMoa0707615.PubMedPubMedCentral
99.
Masuzaky R, Yoshida H, Omata M: Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Oncology. 2010, 78: 17-23. 10.1159/000315225.
100.
Miyake Y, Takaki A, Iwasaki Y, Yamamoto K: Meta-analysis: Interferon-alpha Prevents the Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. J Viral Hepat. 2010, 17 (4): 287-292. 10.1111/j.1365-2893.2009.01181.x.PubMed
101.
Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T, Sezaki H, Akuta N, Suzuki Y, Suzuki F, Kumada H: A longterm glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci. 2006, 51 (3): 603-9. 10.1007/s10620-006-3177-0.PubMed
102.
Group GHCSO: Study on chemoprevention of hepatocellular carcinoma by ginseng: An introduction to the protocol. J Korean Med Sci. 2001, S70-4.
103.
Yu MW, Hsieh HH, Pan WH, Yang CS, Chen CJ: Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res. 1995, 55 (6): 1301-5.PubMed
104.
Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996, 334 (24): 1561-7. 10.1056/NEJM199606133342402.PubMed
105.
Muto Y, Moriwaki H, Saito A: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med. 1999, 340 (13): 1046-7. 10.1056/NEJM199904013401315.PubMed
106.
Yu SY, Zhu YJ, Li WG: Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Boil Trace Elem Res. 1997, 56: 117-124. 10.1007/BF02778987.
107.
Yu S, Li W, Zhu Y, Yu WP, Hou C: Chemoprevention trial of human hepatitis with selenium supplementation in china. Biol Trace Elem Res. 1989, 15-22. 10.1007/BF02919094.
108.
Ito Y, Suzuki K, Ishii J, Hishida H, Tamakoshi A, Hamajima N, Aoki K: A population-based follow-up study on mortality from cancer or cardiovascular disease and serum carotenoids, retinol and tocopherols in japans inhabitants. Asian Pac J Cancer Prev. 2006, 7: 533-546.PubMed
109.
Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC: Prediagnostic leel of serum retinol in relation to reduced risk of hepatocellular carcinoma. J Natl Cancer Inst. 2006, 98: 482-190. 10.1093/jnci/djj104.PubMed
110.
Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S, JPHC Study Group: Vegetable, fruit and antioxidant nutrient consumption and subsequent risk of hepatocellualr carcinoma: a prospective cohort study in Japan. Br J Cancer. 2009, 100: 181-184. 10.1038/sj.bjc.6604843.PubMedPubMedCentral
Metadata
Title
Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment
Authors
Giuseppe Castello
Susan Costantini
Stefania Scala
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2010
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-8-109

Other articles of this Issue 1/2010

Journal of Translational Medicine 1/2010 Go to the issue

Review

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

Research

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

Research

Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma

Research

Decreased level of recent thymic emigrants in CD4+ and CD8+T cells from CML patients

Research

cDNA targets improve whole blood gene expression profiling and enhance detection of pharmocodynamic biomarkers: a quantitative platform analysis

Methodology

One Step Nucleic Acid Amplification (OSNA) - a new method for lymph node staging in colorectal carcinomas
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits